abstract: PURPOSE: Infusion of @entity8 -specific T cells, derived from vaccine-primed @entity1 and expanded with @entity7 /IL12, has induced @entity2 regression in a minority of @entity1 with metastatic treatment-refractory @entity8 (+) @entity0 . We questioned whether alteration of cytokine growth factors used to culture vaccine-primed T cells could improve antitumor activity. EXPERIMENTAL DESIGN: Using the TgMMTV-neu @entity3 @entity2 model, we cultured T cells derived from @entity3 immunized with a previously defined neu class II peptide, p98-114 (neu p98), and evaluated different cytokine combinations for expansion. RESULTS: Infusion of neu p98-specific T-cell lines derived from all cytokine conditions evaluated resulted in significant antitumor activity compared with infused na  ve splenocytes (P < 0.05). T cells cultured with @entity7 / @entity10 could uniquely mediate complete regression of spontaneous @entity2 . @entity7 / @entity10 cultured neu-specific T cells demonstrated a different cytokine secretion pattern as compared with other cultured T cells; secreting high levels of @entity4 and @entity9 (P < 0.05). Moreover, @entity2 -infiltrating @entity5 (+) cells were significantly increased after the infusion of @entity7 / @entity10 cultured T cells as compared with @entity2 treated with T cells expanded under other cytokine conditions (P < 0.001). The antitumor effect of the infusion of @entity7 / @entity10 cultured cells was mediated by @entity5 T cells. Depletion of @entity4 or @entity9 , but not IFNy, abrogated the @entity2 growth inhibition induced by the @entity7 / @entity10 T cells and markedly decreased the influx of @entity5 into @entity2 . Finally, @entity7 / @entity10 -cultured human antigen specific T cells also displayed a similar polyfunctional @entity6 /Th17 phenotype. CONCLUSIONS: Expansion of @entity8 vaccine-primed T cells with @entity7 / @entity10 may have the potential to effectively mediate @entity2 regression when used in adoptive transfer. Clin Cancer Res; 22(9); 2207-16.   2015 AACR.

title: The Antitumor Efficacy of @entity7 / @entity10 -Cultured Polyfunctional Neu-Specific T Cells Is @entity4 / XXXX Dependent.

answer: @entity9


abstract: PURPOSE: Infusion of @entity8 -specific T cells, derived from vaccine-primed @entity1 and expanded with @entity7 /IL12, has induced @entity2 regression in a minority of @entity1 with metastatic treatment-refractory @entity8 (+) @entity0 . We questioned whether alteration of cytokine growth factors used to culture vaccine-primed T cells could improve antitumor activity. EXPERIMENTAL DESIGN: Using the TgMMTV-neu @entity3 @entity2 model, we cultured T cells derived from @entity3 immunized with a previously defined neu class II peptide, p98-114 (neu p98), and evaluated different cytokine combinations for expansion. RESULTS: Infusion of neu p98-specific T-cell lines derived from all cytokine conditions evaluated resulted in significant antitumor activity compared with infused na  ve splenocytes (P < 0.05). T cells cultured with @entity7 / @entity10 could uniquely mediate complete regression of spontaneous @entity2 . @entity7 / @entity10 cultured neu-specific T cells demonstrated a different cytokine secretion pattern as compared with other cultured T cells; secreting high levels of @entity4 and @entity9 (P < 0.05). Moreover, @entity2 -infiltrating @entity5 (+) cells were significantly increased after the infusion of @entity7 / @entity10 cultured T cells as compared with @entity2 treated with T cells expanded under other cytokine conditions (P < 0.001). The antitumor effect of the infusion of @entity7 / @entity10 cultured cells was mediated by @entity5 T cells. Depletion of @entity4 or @entity9 , but not IFNy, abrogated the @entity2 growth inhibition induced by the @entity7 / @entity10 T cells and markedly decreased the influx of @entity5 into @entity2 . Finally, @entity7 / @entity10 -cultured human antigen specific T cells also displayed a similar polyfunctional @entity6 /Th17 phenotype. CONCLUSIONS: Expansion of @entity8 vaccine-primed T cells with @entity7 / @entity10 may have the potential to effectively mediate @entity2 regression when used in adoptive transfer. Clin Cancer Res; 22(9); 2207-16.   2015 AACR.

title: The Antitumor Efficacy of @entity7 / @entity10 -Cultured Polyfunctional Neu-Specific T Cells Is XXXX / @entity9 Dependent.

answer: @entity4


abstract: BACKGROUND _ AIMS: Optimal nutritional care for intensive care unit (ICU) @entity0 requires precise determination of @entity2 ( @entity2 ) to avoid deleterious under- or overfeeding. The reference method, @entity1 ( @entity1 ), is rarely accessible and inconstantly feasible. Various equations for predicting @entity2 based on body weight (BW) are available. This study aims at determining the best prediction strategy unless @entity1 is available. METHODS: Mechanically ventilated @entity0 staying >= 72  h in the ICU were included, except those with contraindications for @entity1 measurements. @entity1 and BW measurements were routinely performed. @entity2 was predicted by the ESPEN formula and other predictive equations using BW (i.e. anamnestic (AN), measured (MES), adjusted for cumulated water balance (ADJ), calculated for a body mass index (BMI) of 22.5). Comparisons were made using Pearson correlation and Bland _ Altman plots. RESULTS: 85 @entity0 (57      19  y, 61 @entity0 , SAPS II 43      16) were included. Correlations between @entity1 and predicted @entity2 using the ESPEN formula with different BW (BWAN, BWMES, BWADJ, and BWBMI22.5) were 0.44, 0.40, 0.36, and 0.47, respectively. Bland _ Altman plots showed wide and inconsistent variations. Predictive equations including body temperature and minute ventilation showed the best correlations, but when using various BWs, differences in predicted @entity2 were observed. CONCLUSION: No @entity2 predictive equation, regardless of the BW used, gives statistically identical results to @entity1 . If @entity1 cannot be performed, predictive equations including minute ventilation and body temperature should be preferred. BW has a significant impact on estimated @entity2 and the use of measured BWMES or BW BMI 22.5 is associated with the best @entity2 prediction. Clinical trial registration number on ClinicalTrial.gov: NCT02552446. Ethical committee number: CE-14-070.

title: Energy expenditure in mechanically ventilated XXXX : The weight of body weight!

answer: @entity0


abstract: UNASSIGNED: Purpose To evaluate the association of @entity2 with visceral @entity1 of @entity3 ( @entity3 ) that does not abut the pleural surface. Materials and Methods This retrospective study was approved by the institutional review board. Informed consent was waived. The study of @entity3 that does not abut the pleura in 141 @entity0 (44 @entity0 [31.2%] with visceral @entity1 proved by pathologic analysis and 97 @entity0 [68.8%] without @entity1 ) was conducted at a single tertiary center. The @entity2 were classified into three types (type 1, one or more linear @entity2 ; type 2, one or more linear @entity2 with soft tissue component at the pleural end; and type 3, one or more soft tissue cord-like @entity2 ) and prioritized into types 3, 2, and 1 when more than one type was present. Diagnostic accuracy, sensitivity, specificity, positive predictive value ( @entity4 ), negative predictive value (NPV), and positive likelihood ratio (LR) were calculated. Results In the absence of @entity2 , no @entity1 was found. The presence of type 2 @entity2 was moderately associated with visceral @entity1 with the following results: positive LR, 5.06; accuracy, 71%; sensitivity, 36.4%; specificity, 92.8%; @entity4 , 76.2%; and NPV, 69.6%. Type 1 @entity2 provided weak evidence to rule out visceral @entity1 (positive LR, 0.38). Type 3 @entity2 indicated minimal increase in the likelihood of visceral @entity1 (positive LR, 1.68). Conclusion Type 2 @entity2 on conventional CT images can increase the accuracy of early diagnosis of visceral @entity1 by @entity3 that does not abut the pleura. (  ) RSNA, 2015.

title: Pleural Tags on CT Scans to Predict Visceral Pleural Invasion of XXXX That Does Not Abut the Pleura.

answer: @entity3


abstract: PURPOSE: To compare the objective and subjective quality of vision after femtosecond laser-assisted small incision lenticule extraction (SMILE) and laser-assisted subepithelial keratomileusis (LASEK) for mild to moderate @entity2 . METHODS: This prospective, comparative study included 65 eyes of 33 @entity0 in the SMILE group, with a mean spherical equivalent (SE) of -4.16    0.82 diopters, and 50 eyes of 25 @entity0 in the LASEK group, with a mean SE of -3.81    0.97 diopters. Visual acuity, corneal topography, contrast sensitivity, and wavefront aberrations were recorded preoperatively and compared with postoperative measurements. A quality of vision questionnaire was scored and analyzed 3 months postoperatively. RESULTS: Three months postoperatively, the SMILE group had fewer (P < .05) higher-order aberrations (HOAs) (0.390    0.175   m), including spherical aberration (SA) (0.262    0.242   m), than the LASEK group (HOAs = 0.479    0.148   m, SA = 0.576    0.287   m, trefoil = 0.465    0.248   m). There was no significant difference in the amount of @entity1 and trefoil between the two groups after surgery. Analysis of the scores of glare and halos in the quality of vision questionnaire revealed that SMILE (night glare = 1.25    1.22, halos = 0.97    1.12) provided a better quality of vision (P < .05) than LASEK (night glare = 2.32    1.99, halos = 1.96    1.77). The two groups demonstrated no significant difference in contrast sensitivity 3 months postoperatively. No vision-threatening complications were noted at any stage in either group. CONCLUSIONS: Both SMILE and LASEK are safe and effective surgical procedures in the correction of @entity2 . SMILE has a lower induction rate of HOAs and a higher degree of @entity0 satisfaction than LASEK at 3 months postoperatively. [J Refract Surg. 2015;31(12):795-800.].

title: Comparison of Visual Quality After SMILE and LASEK for Mild to Moderate XXXX .

answer: @entity2


abstract: UNASSIGNED: Protein drugs are currently delivered by bolus injection and although treatment frequently is successful, these methods also have major drawbacks, which call for the development of alternative technologies allowing prolonged delivery of these drugs. We developed a new ex vivo gene therapy platform called Transduced Autologous Restorative Gene Therapy (TARGT) for sustained long term production and secretion of autologous therapeutic proteins. A biopsy of dermal tissue taken from the @entity0 is transduced ex vivo with a viral vector encoding the required gene under a constitutive promoter. Following measurement of protein secretion ex vivo, the transduced dermal tissue is implanted back into the @entity0 , where it secretes the therapeutic protein into the circulation for several months or longer. A major hurdle to this approach is potential immunogenicity of the transduced tissue following implantation. In this paper we describe the preclinical and early clinical development of this technology, which allowed overcoming these hurdles. To that end, we have used the @entity4 ( @entity4 ) adenoviral vector with newly designed expression cassette containing genetic elements to optimize transgene expression. Moreover, we have developed procedures for TARGT tissue implantation, with measures to improve engraftment and reduce @entity2 and rejection. Implantation of @entity0 TARGT to immune-deficient @entity5 @entity1 indicated long-term production of active proteins in the blood. Preliminary results of a clinical trial from two @entity3 @entity0 , implanted with TARGTs expressing the @entity0 @entity6 ( @entity6 ) gene, demonstrated prolonged secretion with physiologic blood level of the hormone and Hemoglobin maintenance in the desired range, for a period of at least five months without exogenous @entity6 administration. We believe that the TARGT technology has the potential to become a platform for the sustained delivery of therapeutic proteins in various clinical indications.

title: Preclinical and preliminary clinical evaluation of genetically transduced dermal tissue implants for the sustained secretion of XXXX and interferon a.

answer: @entity6


abstract: UNASSIGNED: @entity0 monocytes are a heterogeneous cell population classified into three different subsets: Classical @entity4 ++ @entity3 -, intermediate @entity4 ++ @entity3 +, and non-classical @entity4 + @entity3 ++ monocytes. These subsets are distinguished by their differential expression of @entity4 and @entity3 , and unique gene expression profile. So far, the variation in inter-cellular gene expression within the monocyte subsets is largely unknown. In this study, the cellular variation within each @entity0 monocyte subset from a single healthy donor was described by using a novel single-cell PCR gene-expression analysis tool. We investigated 86 different genes mainly encoding cell surface markers, and proteins involved in immune regulation. Within the three @entity0 monocyte subsets, our descriptive findings show multimodal expression of key immune response genes, such as @entity1 , NF   B1, @entity7 , @entity2 , @entity8 and @entity5 . Furthermore, we discovered one subgroup of cells within the classical monocytes, which showed alterations of 22 genes e.g. @entity9 , @entity1 , @entity6 , @entity7 and TNF. Additionally one subgroup within the intermediate and non-classical monocytes also displayed distinct gene signatures by altered expression of 8 and 6 genes, respectively. Hence the three monocyte subsets can be further subdivided according to activation status and differentiation, independently of the traditional classification based on cell surface markers. Demonstrating the use and the ability to discover cell heterogeneity within defined populations of @entity0 monocytes is of great importance, and can be useful in unravelling inter-cellular variation in leukocyte populations, identifying subpopulations involved in disease pathogenesis and help tailor new therapies.

title: A Single-Cell Gene-Expression Profile Reveals Inter-Cellular Heterogeneity within XXXX Monocyte Subsets.

answer: @entity0


abstract: PURPOSE: Three-dimensional (3D) computed tomography imaging is now being used to generate 3D models for planning orthopaedic surgery, but the process remains time consuming and expensive. For chronic @entity2 , we have designed a graphic overlay approach that employs selected 3D computer images and widely available software to simplify the process of osteotomy site selection. METHODS: We studied 5 @entity0 (2 traumatic and 3 congenital) with unilateral @entity2 . These @entity0 were treated with surgery based on traditional radiographs, but they also had full sets of 3D CT imaging done both before and after their surgery: these 3D CT images form the basis for this study. From the 3D CT images, each @entity0 generated 3 sets of 3D-printed bone models: 2 copies of the preoperative condition, and 1 copy of the @entity1 . One set of the preoperative models was then actually osteotomized and fixed in the manner suggested by our graphic technique. Arcs of rotation of the 3 sets of 3D-printed bone models were then compared. RESULTS: Arcs of rotation of the 3 groups of bone models were significantly different, with the models osteotomized accordingly to our graphic technique having the widest arcs. CONCLUSIONS: For chronic @entity2 , our graphic overlay approach simplifies the selection of the osteotomy site(s). Three-dimensional-printed bone models suggest that this approach could improve range of motion of the forearm in actual surgical practice. LEVEL OF EVIDENCE: Level IV-therapeutic study.

title: A Graphic Overlay Method for Selection of Osteotomy Site in Chronic XXXX : An Evaluation of 3D-printed Bone Models.

answer: @entity2


abstract: INTRODUCTION: Posttraumatic pediatric distal tibiofibular @entity3 is a rare complication following @entity1 . This is a retrospective, multicenter case series of @entity3 of distal tibiofibular @entity1 in @entity0 . The purpose was to evaluate the incidence and pattern of posttraumatic distal tibiofibular @entity3 in @entity0 . METHODS: Of the 604 pediatric distal tibiofibular @entity1 , 20 @entity0 (3.3%) with @entity3 after treatment of distal tibiofibular @entity1 were identified at 3 tertiary referral centers. There were 12 @entity0 and 8 @entity0 , with a mean age of 8.4  2.0 years (range, 3.7 to 11.5 y) at the time of injury. Medical records were reviewed, and serial radiographs were analyzed to determine @entity1 configuration, pattern of @entity3 , and changes in the relative positions of the proximal and distal tibial and fibular physes and in the alignment of the ankle. RESULTS: The time from the occurrence of @entity1 until the recognition of the @entity3 ranged from 2 to 6 months (mean, 2.8 mo). The most common @entity1 configuration was oblique @entity1 combined with comminuted fibular @entity1 . There were 12 focal types and 8 extensive types. The proximal tibiofibular distance was decreased in 13 @entity0 . Proximal migration of the distal fibular physis developed in all cases. Five @entity0 exhibited ankle valgus of 10 degrees or greater with moderate or severe distal fibular shortening. Eight @entity0 were symptomatic after @entity3 and 12 @entity0 were asymptomatic. CONCLUSIONS: We identified 2 patterns of @entity3 after the treatment of pediatric distal tibiofibular @entity1 : focal and extensive. The focal type was more prevalent than the extensive type, which was more likely to occur due to high-energy injury. When a tibiofibular cross-union develops, it creates growth abnormalities that warrant observation and potential treatment, as it may lead to progressive @entity2 . LEVEL OF EVIDENCE: Level IV.

title: Posttraumatic Tibiofibular Synostosis After Treatment of Distal Tibiofibular Fractures in XXXX .

answer: @entity0


abstract: UNASSIGNED: Insect pollination, despite its potential to contribute substantially to crop production, is not an integrated part of agronomic planning. A major reason for this are knowledge gaps in the contribution of pollinators to yield, which partly result from difficulties in determining area-based estimates of yield effects from insect pollination under field conditions. We have experimentally manipulated @entity1 @entity1 densities at 43 @entity0 @entity0 fields over 2 years in Scandinavia. @entity1 hives were placed in 22 fields; an additional 21 fields without large apiaries in the surrounding landscape were selected as controls. Depending on the pollination system in the parental generation, the @entity0 cultivars in the crop fields are classified as either open-pollinated or first-generation hybrids, with both types being open-pollinated in the generation of plants cultivated in the fields. Three cultivars of each type were grown. We measured the activity of flower-visiting insects during flowering and estimated yields by harvesting with small combine harvesters. The addition of @entity1 hives to the fields dramatically increased abundance of flower-visiting @entity1 in those fields. @entity1 affected yield, but the effect depended on cultivar type (p  =  0.04). Post-hoc analysis revealed that open-pollinated cultivars, but not hybrid cultivars, had 11% higher yields in fields with added @entity1 than those grown in the control fields (p  =  0.07). To our knowledge, this is the first whole-field study in replicated landscapes to assess the benefit of insect pollination in @entity0 . Our results demonstrate that @entity1 have the potential to increase @entity0 yields, thereby emphasizing the importance of pollinator management for optimal cultivation of @entity0 .

title: Large-scale pollination experiment demonstrates the importance of insect pollination in winter XXXX .

answer: @entity0


abstract: UNASSIGNED: The presence or absence of @entity3 and @entity4 steroid hormone receptor expression (ER, PR) is an essential feature of invasive @entity0 and determines prognosis and endocrine treatment decisions. Among the four ER/PR receptor phenotypes, the ER-/PR+ is infrequent, and its clinical relevance has been controversially discussed. Thus, we investigated its clinical significance and gene expression pattern in large datasets. In a retrospective clinical study of 15,747 @entity0 @entity1 , we determined the ER/PR subtype survival probabilities using Kaplan-Meier and Cox regression analyses. From The @entity2 (TCGA) @entity0 dataset, PAM50 expression signature and pathway analyses were performed to test for distinct molecular features. In our cohort, the ER-/PR+ phenotype has been observed at a frequency of 4.1  % and was associated with an improved 10-year survival for stage I @entity2 compared to the ER+/PR+ reference subtype (median; 95  % CI 88.1  %; 83-93 vs. 84.3  %; 82-86  %, P  =  0.024) as was confirmed by multivariate analysis over the entire follow-up (HR 0.59, 95  % CI 0.38-0.92, P  =  0.021). This association lacked significance when including all stages. ER-/PR+ @entity1 treated with antihormonal agents (34.5  %) had shorter survival compared to their non-treated counterparts (Log-rank P  =  0.0001). PAM50 signatures suggest a distinct configuration for the ER-/PR+ phenotype. This specific phenotype has been further separated by a set of 59 uniquely expressed genes. Our study supports the notion of the existence of an ER-/PR+ phenotype with clinical and molecular features distinct from the large group of ER+/PR+ @entity1 .

title: Clinical outcome and global gene expression data support the existence of the @entity3 receptor-negative/ @entity4 receptor-positive invasive XXXX phenotype.

answer: @entity0


abstract: UNASSIGNED: The presence or absence of @entity3 and @entity4 steroid hormone receptor expression (ER, PR) is an essential feature of invasive @entity0 and determines prognosis and endocrine treatment decisions. Among the four ER/PR receptor phenotypes, the ER-/PR+ is infrequent, and its clinical relevance has been controversially discussed. Thus, we investigated its clinical significance and gene expression pattern in large datasets. In a retrospective clinical study of 15,747 @entity0 @entity1 , we determined the ER/PR subtype survival probabilities using Kaplan-Meier and Cox regression analyses. From The @entity2 (TCGA) @entity0 dataset, PAM50 expression signature and pathway analyses were performed to test for distinct molecular features. In our cohort, the ER-/PR+ phenotype has been observed at a frequency of 4.1  % and was associated with an improved 10-year survival for stage I @entity2 compared to the ER+/PR+ reference subtype (median; 95  % CI 88.1  %; 83-93 vs. 84.3  %; 82-86  %, P  =  0.024) as was confirmed by multivariate analysis over the entire follow-up (HR 0.59, 95  % CI 0.38-0.92, P  =  0.021). This association lacked significance when including all stages. ER-/PR+ @entity1 treated with antihormonal agents (34.5  %) had shorter survival compared to their non-treated counterparts (Log-rank P  =  0.0001). PAM50 signatures suggest a distinct configuration for the ER-/PR+ phenotype. This specific phenotype has been further separated by a set of 59 uniquely expressed genes. Our study supports the notion of the existence of an ER-/PR+ phenotype with clinical and molecular features distinct from the large group of ER+/PR+ @entity1 .

title: Clinical outcome and global gene expression data support the existence of the @entity3 receptor-negative/ XXXX receptor-positive invasive @entity0 phenotype.

answer: @entity4


abstract: UNASSIGNED: The presence or absence of @entity3 and @entity4 steroid hormone receptor expression (ER, PR) is an essential feature of invasive @entity0 and determines prognosis and endocrine treatment decisions. Among the four ER/PR receptor phenotypes, the ER-/PR+ is infrequent, and its clinical relevance has been controversially discussed. Thus, we investigated its clinical significance and gene expression pattern in large datasets. In a retrospective clinical study of 15,747 @entity0 @entity1 , we determined the ER/PR subtype survival probabilities using Kaplan-Meier and Cox regression analyses. From The @entity2 (TCGA) @entity0 dataset, PAM50 expression signature and pathway analyses were performed to test for distinct molecular features. In our cohort, the ER-/PR+ phenotype has been observed at a frequency of 4.1  % and was associated with an improved 10-year survival for stage I @entity2 compared to the ER+/PR+ reference subtype (median; 95  % CI 88.1  %; 83-93 vs. 84.3  %; 82-86  %, P  =  0.024) as was confirmed by multivariate analysis over the entire follow-up (HR 0.59, 95  % CI 0.38-0.92, P  =  0.021). This association lacked significance when including all stages. ER-/PR+ @entity1 treated with antihormonal agents (34.5  %) had shorter survival compared to their non-treated counterparts (Log-rank P  =  0.0001). PAM50 signatures suggest a distinct configuration for the ER-/PR+ phenotype. This specific phenotype has been further separated by a set of 59 uniquely expressed genes. Our study supports the notion of the existence of an ER-/PR+ phenotype with clinical and molecular features distinct from the large group of ER+/PR+ @entity1 .

title: Clinical outcome and global gene expression data support the existence of the XXXX receptor-negative/ @entity4 receptor-positive invasive @entity0 phenotype.

answer: @entity3


abstract: STUDY DESIGN: Investigation of the effects of the impairment of different nutritional pathways on the @entity1 patterns in terms of spatial distributions of cell density, glycosaminoglycan content, and water content. OBJECTIVE: The aim of this study was to test the hypothesis that impairment of different nutritional pathways would result in different degenerative patterns in @entity0 discs. SUMMARY OF BACKGROUND DATA: Impairment of nutritional pathways has been found to affect cell viability in the disc. However, details on how impairment of different nutritional pathways affects the @entity1 patterns are unknown. METHODS: A 3D finite element model was used for this study. This finite element method was based on the cell-activity coupled mechano-electrochemical theory for cartilaginous tissues. Impairment of the nutritional pathways was simulated by lowering the nutrition level at the disc boundaries. Effects of the impartment of cartilaginous endplate-nucleus pulposus (CEP-NP) pathway only (Case 1), annulus fibrosus (AF) pathway only (Case 2), and both pathways (Case 3) on @entity1 patterns were studied. RESULTS: The predicted critical levels of nutrition for Case 1, Case 2, and Case 3 were around 30%, 20%, and 50% of the reference values, respectively. Below this critical level, the @entity1 would occur. @entity1 appeared mainly in the NP for Case 1, in the outer AF for Case 2, and in both the NP and inner to middle AF for Case 3. For Cases 1 and 3, the loss of water content was primarily located in the mid-axial plane, which is consistent with the horizontal gray band seen in some T2-weighted magnetic resonance imaging (MRI). For the disc geometry used in this study, it was predicted that there existed a high-intensity zone (for Case 3), as seen in some T2-weighted MRI images. CONCLUSION: Impairment of different nutrition pathways results in different degenerative patterns. LEVEL OF EVIDENCE: N/A.

title: Influences of Nutrition Supply and Pathways on the Degenerative Patterns in XXXX Intervertebral Disc.

answer: @entity0


abstract: This study is aimed at providing a dosimetric evaluation of the irregular motion of @entity1 due to variations in @entity0 ' respiration. Twenty-three @entity1 @entity0 are retrospectively enrolled in this study. The motion of the @entity0 clinical target volume is simulated and two types of irregularities are defined: characteristic and uncharacteristic motions. Characteristic irregularities are representative of random fluctuations in the observed target motion. Uncharacteristic irregular motion is classified as systematic errors in determination of the target motion during the planning session. Respiratory traces from measurement of @entity0 abdominal motion are also used for the target motion simulations. Characteristic irregular motion was observed to cause minimal changes in target dosimetry with the largest effect of 2.5%    0.9% (1  ) reduction in the minimum target dose (D(min)) observed for targets that move 2 cm on average and exhibiting 50% amplitude variations within a session. However, uncharacteristic irregular motion introduced more drastic changes in the clinical target volume (CTV) dose; 4.1%    1.7% reduction for 1 cm motion and 9.6%    1.7% drop for 2 cm. In simulations with @entity0 ' abdominal motion, corresponding changes in target dosimetry were observed to be negligible (<0.1%). Only uncharacteristic irregular motion was identified as a clinically significant source of dosimetric uncertainty.

title: A simulation study of irregular respiratory motion and its dosimetric impact on XXXX .

answer: @entity1


abstract: PURPOSE: To evaluate the long-term corneal safety of topical @entity1 ( @entity2 ) used during photorefractive keratectomy to prevent haze formation in highly myopic eyes. METHODS: Twenty-eight @entity0 with bilateral high @entity3 underwent photorefractive keratectomy. One eye was randomly assigned to intraoperative 0.02% @entity2 and the fellow eye to conventional treatment. Each eye was checked at baseline and at 5 years after surgery using in vivo corneal confocal microscopy. RESULTS: At baseline, the endothelial cell density was 2970    295 cells per square millimeter in the @entity2 -treated eyes and 2839    323 cells per square millimeter in the control eyes. At 5 years, it was 2803    307 and 2780    264 cells per square millimeter, respectively (P = 0.27). The number of @entity4 fibers was 3.9    1.6 in the @entity2 -treated eyes and 4.4    1.3 in the control eyes. At 5 years, it was 3.0    1.6 and 2.7    1.3, respectively (P = 0.15). The density of corneal nerves was 9600    2915  m/mm(2) in the @entity2 -treated eyes and 11,352    3898  m/mm(2) in the control eyes. At 5 years, the density was higher in the @entity2 -treated eyes (6790    2447  m/mm(2)) than in the control eyes (6024    2977  m/mm(2)) (P = 0.003). The number of nerve beadings at baseline was 12.9    1.7/100  m in the @entity2 -treated eyes and 12.3    2.0/100  m in the control eyes. At 5 years, it was 9.9    2.6/100 and 9.4    2.9/100  m, respectively (P = 1.00). At 5 years, @entity4 branching and tortuosity were similar in the 2 groups (P = 0.88 and 0.54, respectively). Epithelium thickness remained statistically unchanged (P = 0.69). CONCLUSIONS: Intraoperative use of topical 0.02% @entity2 compared with standard treatment does not induce significant long-term corneal changes, as assessed by in vivo corneal confocal microscopy.

title: XXXX -assisted photorefractive keratectomy in high @entity3 : a long-term safety study.

answer: @entity1


abstract: PURPOSE: To evaluate the long-term corneal safety of topical @entity1 ( @entity2 ) used during photorefractive keratectomy to prevent haze formation in highly myopic eyes. METHODS: Twenty-eight @entity0 with bilateral high @entity3 underwent photorefractive keratectomy. One eye was randomly assigned to intraoperative 0.02% @entity2 and the fellow eye to conventional treatment. Each eye was checked at baseline and at 5 years after surgery using in vivo corneal confocal microscopy. RESULTS: At baseline, the endothelial cell density was 2970    295 cells per square millimeter in the @entity2 -treated eyes and 2839    323 cells per square millimeter in the control eyes. At 5 years, it was 2803    307 and 2780    264 cells per square millimeter, respectively (P = 0.27). The number of @entity4 fibers was 3.9    1.6 in the @entity2 -treated eyes and 4.4    1.3 in the control eyes. At 5 years, it was 3.0    1.6 and 2.7    1.3, respectively (P = 0.15). The density of corneal nerves was 9600    2915  m/mm(2) in the @entity2 -treated eyes and 11,352    3898  m/mm(2) in the control eyes. At 5 years, the density was higher in the @entity2 -treated eyes (6790    2447  m/mm(2)) than in the control eyes (6024    2977  m/mm(2)) (P = 0.003). The number of nerve beadings at baseline was 12.9    1.7/100  m in the @entity2 -treated eyes and 12.3    2.0/100  m in the control eyes. At 5 years, it was 9.9    2.6/100 and 9.4    2.9/100  m, respectively (P = 1.00). At 5 years, @entity4 branching and tortuosity were similar in the 2 groups (P = 0.88 and 0.54, respectively). Epithelium thickness remained statistically unchanged (P = 0.69). CONCLUSIONS: Intraoperative use of topical 0.02% @entity2 compared with standard treatment does not induce significant long-term corneal changes, as assessed by in vivo corneal confocal microscopy.

title: @entity1 -assisted photorefractive keratectomy in high XXXX : a long-term safety study.

answer: @entity3


abstract: PURPOSE: Granular corneal @entity4 (GCD2) causes the formation of @entity3 having 3 different morphological types. We used Fourier domain optical coherence tomography to assess the depths of each type according to the morphology. METHODS: A prospective study was performed in 54 eyes of 54 heterozygous @entity0 with GCD2. @entity3 of 54 @entity0 with GCD2 were classified into 3 morphological types: type 1, diffuse haze; type 2, granular shape (2 subgroups: type 2a, round granulated and type 2b, round spiculated); and type 3, linear shape (2 subgroups: type 3a, short side branched and type 3b, long side branched). Using Fourier domain optical coherence tomography, we measured the distances from the Bowman layer to the upper surface of @entity2 (USBL), to the lower surface of @entity2 (LSBL), and the thickness of @entity2 ( @entity2 ). The deposits formed along the flap interface were also examined among 19 @entity0 who had LASIK. RESULTS: Types 1 and 2 deposits were always adjacent to the Bowman layer; thus the USBLs for each were 0.0    0.0  m, whereas that of type 3 deposits was 65.4    48.0  m (P < 0.0001). The LSBL and @entity2 with long side branches (type 3) (313.3    71.4 and 246.2    71.9  m) were greater than those of type 1 (47.7    10.2 and 47.7    10.2  m) and type 2 (91.3    39.5 and 91.3    39.5  m) (P < 0.0001). There were no differences in the measurements between the subgroups type 2a and type 2b or between types 3a and 3b. USBL of the laser in situ keratomileusis group was 54.5    29.8  m. CONCLUSIONS: The depths of @entity3 in @entity0 with GCD2 were associated with the morphology of @entity2 . The linear deposits were located most deeply in the @entity1 , followed by granular deposits and diffuse haze moving anteriorly. Several deposits have distinct depths according to the morphological types.

title: Analysis of deposit depth and morphology in granular corneal XXXX using fourier domain optical coherence tomography.

answer: @entity4


abstract: BACKGROUND: In recent years, immunohistochemistry has emerged as an efficient tool in the detection of DNA mismatch repair protein abnormality in @entity2 . Currently, the immunohistochemical test is mainly applied to cancer resection specimens. Detection of mismatch repair abnormality in biopsies carries obvious clinical importance, as it would allow informed decision about the extent of surgery (segmental resection vs total colectomy, prophylactic hysterectomy or not). Moreover, in the case of treated @entity4 with no @entity3 , it provides a means to evaluate the mismatch repair proteins. However, whether biopsy samples can be reliably used for mismatch repair protein detection remains to be determined. MATERIALS AND METHODS: Paired biopsy and resection specimens of @entity5 of the gastrointestinal tract, enriched for @entity0 at increased risk for @entity7 , were analyzed for immunohistochemical staining patterns for @entity10 , @entity8 , @entity9 , and @entity11 . Abnormal staining was defined as total loss of protein in the @entity1 with appropriate control. Cases with focal and weak staining, defined as staining of no more than moderate intensity present in <10% of the @entity1 cells, were recorded. Correlation analysis with germline mutation data was in a subset of cases. RESULTS: Among 70 @entity6 (3 from the small bowel, 36 from the right colon, 15 from the left colon, and 16 from the anorectum), both the biopsy and resection specimens detected the same 29 @entity1 as having loss of staining for at least 1 protein, 14 affecting @entity10 / @entity11 and 15 affecting @entity8 / @entity9 . Focal and weak staining was most commonly seen for @entity10 stain in biopsies (4 of 70, 6%), followed by @entity9 stain in biopsies (3 of 70, 4%). Concordant staining patterns between biopsies and resections were reached in all 70 cases for @entity8 and @entity11 , whereas discordant patterns were identified in 3 cases (3 of 70, 4%) for @entity10 and in 2 cases (2 of 70, 3%) for @entity9 . None of the discordant patterns affected the final interpretation of whether the immunohistochemistry test was normal or abnormal in either the biopsy or the resection. In 13 of the 13 cases that were known to have a pathogenic germline mutation (5 in @entity10 in @entity8 ), the stains were abnormal for the corresponding protein and/or its partner protein in both the biopsy and the resection specimens. CONCLUSIONS: This study provides data indicating that biopsy samples are as reliable as resections in the immunohistochemical detection of mismatch repair protein abnormality in @entity1 . Our study also shows that various staining variations can occur in both biopsies and resections. Awareness and further understanding of such variations will enhance the use of immunohistochemistry, a commonplace tool that is being increasingly used in the screening workup for @entity7 .

title: Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract XXXX : how reliable are biopsy samples?

answer: @entity4


abstract: OBJECTIVES:: The significance of the association between many gastrointestinal (GI) pathologies and @entity3 has yet to be discovered. The aim of the present study was to review available evidence documenting any link between @entity3 and GI histopathology in @entity0 . MATERIALS AND METHODS:: In a systematic review, the following sources were searched: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1980-August week 2, 2009), EMBASE (1980-August week 2, 2009), PubMed (last 180 days), Web of Science, and Scopus, using the terms " @entity3 " or " @entity1 ." In addition, relevant studies were identified through browsing the reference lists of the included articles for relevant citations. All @entity0 younger than 18 years old with @entity3 who were examined for abnormal GI histopathology were included. Cohort studies published in the English language, reporting GI histopathological examination findings in @entity0 with @entity3 , were included. Two independent authors performed data extraction. The methodological quality of each trial was assessed. RESULTS:: Eight studies have reported the histopathological features of the GI tract in @entity0 with @entity3 and fulfilled inclusion criteria. In general, none of these trials appeared to be of high quality. Apart from @entity2 , the majority of these findings were not consistent. CONCLUSIONS:: GI pathological findings in @entity0 with @entity3 have been inconsistent. The present available evidence does not support or refute a link between GI histopathology and @entity3 in @entity0 . The significance of @entity2 in these @entity0 is unknown. Large properly designed prospective controlled trials addressing this issue are required.

title: Abnormal Gastrointestinal Histopathology in XXXX With Autism Spectrum Disorders.

answer: @entity0


abstract: ETHNOPHARMACOLOGICAL RELEVANCE: Huang-Lian-Jie-Du-Decoction (HLJDD) is a Traditional Chinese Medicine (TCM) clinical prescription noted for its neuroprotective effects. The total alkaloids, @entity5 , and @entity10 are the main active components of HLJDD. In the present study we explored the possible effects of the total alkaloids, @entity5 , and @entity10 from HLJDD on behavioral recovery and cortical neurogenesis after @entity1 . METHODS: The @entity1 model was induced by permanent @entity3 (pMACO). The total alkaloids (44mg/kg), @entity5 (50mg/kg), and @entity10 (80mg/kg) from HLJDD were orally administered for 2 hours after @entity1 and daily thereafter. Neurological function was assessed and then @entity0 were sacrificed 7 days after pMACO. Following repeated intraperitoneal injections of the cell proliferation-specific marker @entity2 ( @entity2 ) after @entity1 induction, precursor cell proliferation and differentiation was monitored by immunofluorescent staining. The levels of relevant proteins were determined by western blotting and the mRNA expressions were assessed by quantitative real time-polymerase chain reaction (qRT-PCR). RESULTS: Total alkaloids, @entity5 and @entity10 from HLJDD showed improved functional outcome after @entity4 . The total alkaloids and @entity10 increased number of @entity2 -positive cells and enhanced neuronal differentiation in the cortex. Alkaloids-enhanced neurogenesis might be associated with increased @entity6 , @entity8 , and @entity9 protein expression. And the neuroproliferative effect of alkaloids was partially correlated with increased phosphorylation of AKT, and @entity7 . @entity5 treatment was found to promote differentiation of cortical precursor cells into neuronal but not glial cells, which may be at least attributable to the regulation of AKT, @entity7 mRNA and @entity8 protein levels. CONCLUSIONS: Total alkaloids, @entity10 and @entity5 from HLJDD promoted functional recovery likely via enhancing cortical neurogenesis and thus have potential as a treatment for @entity4 .

title: Induced Cortical Neurogenesis after Focal XXXX - Three Active Components from Huang-Lian-Jie-Du Decoction.

answer: @entity4


abstract: Inherited and acquired changes in pre-mRNA processing have significant roles in @entity0 diseases, especially @entity1 . Characterization of aberrantly spliced mRNAs may thus contribute to understand malignant transformation. We recently reported an anti-oncogenic potential for the @entity6 transcription factor in the colon. For instance, the @entity3 gene knock out in the @entity2 intestine results in an excess of proliferation with appearance of @entity5 . @entity6 is expressed in @entity4 cells but its endogenous activity is weak. We looked for @entity6 variants that may impair @entity6 activity in @entity4 cells and we discovered MiniSOX9, a truncated version of @entity6 devoid of transactivation domain as a result of retention of the second intron. A significant overexpression of MiniSOX9 mRNA in @entity0 @entity1 samples compared with their matched normal tissues was observed by real-time reverse transcriptase-PCR. Immunohistochemistry revealed that MiniSOX9 is expressed at high levels in @entity0 @entity4 samples whereas it is undetectable in the surrounding healthy tissues. Finally, we discovered that MiniSOX9 behaves as a @entity6 inhibitor, inhibits protein kinase Ca promoter activity and stimulates the canonical Wnt pathway. This potential oncogenic activity of the @entity6 locus gives new insights on its role in @entity4 .

title: MiniSOX9, a dominant-negative variant in XXXX cells.

answer: @entity4


abstract: Splint therapy is a widely used modality for @entity2 ( @entity2 ). However, questions remain regarding the mechanism of symptom relief. Recently, a relation between @entity4 and a discrepancy between the habitual occlusal position (HOP) and the anterior flat plane bite plate-induced occlusal position (BPOP) has been reported. Therefore, to understand the mechanism of the symptom relief associated with the use of a bite plate, the changes in both the HOP and BPOP values were observed during anterior bite plate treatment in a @entity0 with @entity4 . CASE PRESENTATION: Anterior bite plate treatment was started in a @entity0 complaining of @entity3 . A discrepancy between the HOP and BPOP values was recorded three days after the first visit; this discrepancy disappeared on day 6, and the disappearance was maintained between days 6 and 12. The disappearance was associated with a decrease in the severity of the @entity0 's symptoms; however, the discrepancy reappeared after 15 days, coinciding with the complete disappearance of the @entity0 's symptoms. Therefore, the effect of the bite plate on the resolution of the discrepancy between the HOP and BPOP values was interpreted as being unsustainable and occlusal equilibration for the BPOP was performed at 17 days. Thereafter, neither a discrepancy in the HOP and BPOP values nor any symptoms of @entity4 (right temporomandibular joint @entity1 or limited jaw opening) reoccurred during a two-year follow-up period. CONCLUSION: Within the limitations of the present study, the symptom-relieving action of an anterior flat plane bite plate on the resolution of occlusal discrepancy appeared to be temporary. This outcome supports previously reported conclusions that the effectiveness of stabilization splint therapy for reducing symptoms in @entity0 with @entity1 does not differ significantly from that of other conservative therapies or of no treatment at all.

title: A case report of the symptom-relieving action of an anterior flat plane bite plate for XXXX .

answer: @entity2


abstract: BACKGROUND: @entity1 ( @entity1 ) is an aggressive extranodal @entity4 confined to the central nervous system. In this article, we report the results of a pilot trial adding rituximab to the established regimen consisting of @entity3 , @entity5 , and @entity6 (R-MCP). DESIGN AND METHODS: @entity1 @entity0 >= 65 years without Karnofsky performance score (KPS) limit were included. R-MCP regimen consisted of rituximab (375 mg/m(2) i.v. on days -6, 1, 15, and 29), @entity3 (3 g/m(2) i.v., days 2, 16, and 30) followed by folinic rescue, @entity5 (60 mg/m(2) orally, days 2-11), and @entity6 (110 mg/m(2) orally, day 2). A maximum of three 43-day cycles were applied. Primary end point was response to treatment obtained by magnetic resonance imaging. Secondary end points were @entity2 ( @entity2 ) and progression-free survival (PFS). RESULTS: Twenty-eight @entity0 were included (median age 75, median KPS 60%). Best documented response: complete remission in 18 of 28 (64%), partial remission in 5 of 28 (18%), stable disease in 1 of 28 (4%), and progressive disease in 2 of 28 (7%) @entity0 . Response was not assessed in two @entity0 . Two treatment-associated deaths were observed. After a median follow-up of 36 months, the 3-year PFS and @entity2 was 31%. CONCLUSION: R-MCP regimen is well tolerated and active in elderly @entity0 with newly diagnosed @entity1 .

title: Immunochemotherapy with rituximab, @entity3 , XXXX , and @entity6 for primary CNS lymphoma ( @entity1 ) in the elderly.

answer: @entity5


abstract: BACKGROUND: @entity1 ( @entity1 ) is an aggressive extranodal @entity4 confined to the central nervous system. In this article, we report the results of a pilot trial adding rituximab to the established regimen consisting of @entity3 , @entity5 , and @entity6 (R-MCP). DESIGN AND METHODS: @entity1 @entity0 >= 65 years without Karnofsky performance score (KPS) limit were included. R-MCP regimen consisted of rituximab (375 mg/m(2) i.v. on days -6, 1, 15, and 29), @entity3 (3 g/m(2) i.v., days 2, 16, and 30) followed by folinic rescue, @entity5 (60 mg/m(2) orally, days 2-11), and @entity6 (110 mg/m(2) orally, day 2). A maximum of three 43-day cycles were applied. Primary end point was response to treatment obtained by magnetic resonance imaging. Secondary end points were @entity2 ( @entity2 ) and progression-free survival (PFS). RESULTS: Twenty-eight @entity0 were included (median age 75, median KPS 60%). Best documented response: complete remission in 18 of 28 (64%), partial remission in 5 of 28 (18%), stable disease in 1 of 28 (4%), and progressive disease in 2 of 28 (7%) @entity0 . Response was not assessed in two @entity0 . Two treatment-associated deaths were observed. After a median follow-up of 36 months, the 3-year PFS and @entity2 was 31%. CONCLUSION: R-MCP regimen is well tolerated and active in elderly @entity0 with newly diagnosed @entity1 .

title: Immunochemotherapy with rituximab, XXXX , @entity5 , and @entity6 for primary CNS lymphoma ( @entity1 ) in the elderly.

answer: @entity3


abstract: BACKGROUND: @entity1 ( @entity1 ) is an aggressive extranodal @entity4 confined to the central nervous system. In this article, we report the results of a pilot trial adding rituximab to the established regimen consisting of @entity3 , @entity5 , and @entity6 (R-MCP). DESIGN AND METHODS: @entity1 @entity0 >= 65 years without Karnofsky performance score (KPS) limit were included. R-MCP regimen consisted of rituximab (375 mg/m(2) i.v. on days -6, 1, 15, and 29), @entity3 (3 g/m(2) i.v., days 2, 16, and 30) followed by folinic rescue, @entity5 (60 mg/m(2) orally, days 2-11), and @entity6 (110 mg/m(2) orally, day 2). A maximum of three 43-day cycles were applied. Primary end point was response to treatment obtained by magnetic resonance imaging. Secondary end points were @entity2 ( @entity2 ) and progression-free survival (PFS). RESULTS: Twenty-eight @entity0 were included (median age 75, median KPS 60%). Best documented response: complete remission in 18 of 28 (64%), partial remission in 5 of 28 (18%), stable disease in 1 of 28 (4%), and progressive disease in 2 of 28 (7%) @entity0 . Response was not assessed in two @entity0 . Two treatment-associated deaths were observed. After a median follow-up of 36 months, the 3-year PFS and @entity2 was 31%. CONCLUSION: R-MCP regimen is well tolerated and active in elderly @entity0 with newly diagnosed @entity1 .

title: Immunochemotherapy with rituximab, @entity3 , @entity5 , and @entity6 for primary CNS lymphoma ( XXXX ) in the elderly.

answer: @entity1


abstract: BACKGROUND: @entity1 ( @entity1 ) is an aggressive extranodal @entity4 confined to the central nervous system. In this article, we report the results of a pilot trial adding rituximab to the established regimen consisting of @entity3 , @entity5 , and @entity6 (R-MCP). DESIGN AND METHODS: @entity1 @entity0 >= 65 years without Karnofsky performance score (KPS) limit were included. R-MCP regimen consisted of rituximab (375 mg/m(2) i.v. on days -6, 1, 15, and 29), @entity3 (3 g/m(2) i.v., days 2, 16, and 30) followed by folinic rescue, @entity5 (60 mg/m(2) orally, days 2-11), and @entity6 (110 mg/m(2) orally, day 2). A maximum of three 43-day cycles were applied. Primary end point was response to treatment obtained by magnetic resonance imaging. Secondary end points were @entity2 ( @entity2 ) and progression-free survival (PFS). RESULTS: Twenty-eight @entity0 were included (median age 75, median KPS 60%). Best documented response: complete remission in 18 of 28 (64%), partial remission in 5 of 28 (18%), stable disease in 1 of 28 (4%), and progressive disease in 2 of 28 (7%) @entity0 . Response was not assessed in two @entity0 . Two treatment-associated deaths were observed. After a median follow-up of 36 months, the 3-year PFS and @entity2 was 31%. CONCLUSION: R-MCP regimen is well tolerated and active in elderly @entity0 with newly diagnosed @entity1 .

title: Immunochemotherapy with rituximab, @entity3 , @entity5 , and XXXX for primary CNS lymphoma ( @entity1 ) in the elderly.

answer: @entity6


abstract: Homeopathic arnica is widely believed to control @entity5 , reduce swelling and promote recovery after local @entity1 ; many @entity0 therefore take it perioperatively. To determine whether this treatment has any effect, we conducted a double-blind, placebo-controlled, randomized trial with three parallel arms. 64 adults undergoing elective surgery for @entity4 were randomized to take three tablets daily of homeopathic arnica 30C or 6C or placebo for seven days before surgery and fourteen days after surgery. Primary outcome measures were @entity2 (short form McGill Pain Questionnaire) and @entity5 (colour separation analysis) at four days after surgery. Secondary outcome measures were swelling (wrist circumference) and use of analgesic medication ( @entity0 diary). 62 @entity0 could be included in the intention-to-treat analysis. There were no group differences on the primary outcome measures of @entity2 (P=0.79) and @entity5 (P=0.45) at day four. Swelling and use of analgesic medication also did not differ between arnica and placebo groups. Adverse events were reported by 2 @entity0 in the arnica 6C group, 3 in the placebo group and 4 in the arnica 30C group. The results of this trial do not suggest that homeopathic arnica has an advantage over placebo in reducing @entity3 , @entity5 and swelling in @entity0 undergoing elective hand surgery.

title: Homeopathic arnica for prevention of @entity2 and XXXX : randomized placebo-controlled trial in hand surgery.

answer: @entity5


abstract: Homeopathic arnica is widely believed to control @entity5 , reduce swelling and promote recovery after local @entity1 ; many @entity0 therefore take it perioperatively. To determine whether this treatment has any effect, we conducted a double-blind, placebo-controlled, randomized trial with three parallel arms. 64 adults undergoing elective surgery for @entity4 were randomized to take three tablets daily of homeopathic arnica 30C or 6C or placebo for seven days before surgery and fourteen days after surgery. Primary outcome measures were @entity2 (short form McGill Pain Questionnaire) and @entity5 (colour separation analysis) at four days after surgery. Secondary outcome measures were swelling (wrist circumference) and use of analgesic medication ( @entity0 diary). 62 @entity0 could be included in the intention-to-treat analysis. There were no group differences on the primary outcome measures of @entity2 (P=0.79) and @entity5 (P=0.45) at day four. Swelling and use of analgesic medication also did not differ between arnica and placebo groups. Adverse events were reported by 2 @entity0 in the arnica 6C group, 3 in the placebo group and 4 in the arnica 30C group. The results of this trial do not suggest that homeopathic arnica has an advantage over placebo in reducing @entity3 , @entity5 and swelling in @entity0 undergoing elective hand surgery.

title: Homeopathic arnica for prevention of XXXX and @entity5 : randomized placebo-controlled trial in hand surgery.

answer: @entity2


abstract: Inhibition of dephosphorylation of the 20 kDa myosin light chain (MLC(20)) is an important mechanism for the @entity1 -induced sensitization of vascular smooth muscle contraction. We investigated whether this mechanism operates in @entity4 (PGF(2alpha))-induced contraction of @entity0 aortic smooth muscle and, if so, whether @entity8 ( @entity8 ) or rho-associated kinase (rho kinase) contribute to the inhibition of dephosphorylation. In normal medium, @entity4 (10 microM) increased the phosphorylation of MLC(20) and developed @entity3 . The rho-kinase inhibitors @entity9 and @entity13 inhibited these changes, despite having no effect on a @entity7 -induced MLC(20) phosphorylation. After treatment with @entity2 or chelation of external @entity1 with @entity6 , @entity4 increased the MLC(20) phosphorylation and @entity3 without an increase in [ @entity1 ](i), all of which were sensitive to @entity9 and @entity13 . @entity10 , a MLC kinase inhibitor, quickly reversed the @entity5 -induced MLC(20) phosphorylation and contraction to the resting level. However, fractions of PGF(2alpha)-induced contraction and MLC(20) phosphorylation were resistant to @entity10 but were sensitive to @entity9 . @entity12 (10 microM), a @entity8 inhibitor, did not affect the phosphorylation of MLC(20) and the @entity3 caused by PGF(2alpha), thus excluding the possibility of the involvement of @entity8 in the PGF(2alpha)-induced MLC(20) phosphorylation. PGF(2alpha) increased phosphorylation at Thr654 of the @entity11 ( @entity11 ) of myosin phosphatase, which is a target of rho kinase, and @entity9 decreased the phosphorylation. These data suggest that the PGF(2alpha)-induced contraction is accompanied by the inhibition of MLC(20) dephosphorylation through rho kinase-induced @entity11 phosphorylation, leading to @entity1 sensitization of contraction. An actin-associated mechanism may also be involved in the PGF(2alpha)-induced sensitization.

title: Essential role of rho kinase in the XXXX sensitization of @entity4 -induced contraction of @entity0 aortae.

answer: @entity1


abstract: Inhibition of dephosphorylation of the 20 kDa myosin light chain (MLC(20)) is an important mechanism for the @entity1 -induced sensitization of vascular smooth muscle contraction. We investigated whether this mechanism operates in @entity4 (PGF(2alpha))-induced contraction of @entity0 aortic smooth muscle and, if so, whether @entity8 ( @entity8 ) or rho-associated kinase (rho kinase) contribute to the inhibition of dephosphorylation. In normal medium, @entity4 (10 microM) increased the phosphorylation of MLC(20) and developed @entity3 . The rho-kinase inhibitors @entity9 and @entity13 inhibited these changes, despite having no effect on a @entity7 -induced MLC(20) phosphorylation. After treatment with @entity2 or chelation of external @entity1 with @entity6 , @entity4 increased the MLC(20) phosphorylation and @entity3 without an increase in [ @entity1 ](i), all of which were sensitive to @entity9 and @entity13 . @entity10 , a MLC kinase inhibitor, quickly reversed the @entity5 -induced MLC(20) phosphorylation and contraction to the resting level. However, fractions of PGF(2alpha)-induced contraction and MLC(20) phosphorylation were resistant to @entity10 but were sensitive to @entity9 . @entity12 (10 microM), a @entity8 inhibitor, did not affect the phosphorylation of MLC(20) and the @entity3 caused by PGF(2alpha), thus excluding the possibility of the involvement of @entity8 in the PGF(2alpha)-induced MLC(20) phosphorylation. PGF(2alpha) increased phosphorylation at Thr654 of the @entity11 ( @entity11 ) of myosin phosphatase, which is a target of rho kinase, and @entity9 decreased the phosphorylation. These data suggest that the PGF(2alpha)-induced contraction is accompanied by the inhibition of MLC(20) dephosphorylation through rho kinase-induced @entity11 phosphorylation, leading to @entity1 sensitization of contraction. An actin-associated mechanism may also be involved in the PGF(2alpha)-induced sensitization.

title: Essential role of rho kinase in the @entity1 sensitization of @entity4 -induced contraction of XXXX aortae.

answer: @entity0


abstract: Inhibition of dephosphorylation of the 20 kDa myosin light chain (MLC(20)) is an important mechanism for the @entity1 -induced sensitization of vascular smooth muscle contraction. We investigated whether this mechanism operates in @entity4 (PGF(2alpha))-induced contraction of @entity0 aortic smooth muscle and, if so, whether @entity8 ( @entity8 ) or rho-associated kinase (rho kinase) contribute to the inhibition of dephosphorylation. In normal medium, @entity4 (10 microM) increased the phosphorylation of MLC(20) and developed @entity3 . The rho-kinase inhibitors @entity9 and @entity13 inhibited these changes, despite having no effect on a @entity7 -induced MLC(20) phosphorylation. After treatment with @entity2 or chelation of external @entity1 with @entity6 , @entity4 increased the MLC(20) phosphorylation and @entity3 without an increase in [ @entity1 ](i), all of which were sensitive to @entity9 and @entity13 . @entity10 , a MLC kinase inhibitor, quickly reversed the @entity5 -induced MLC(20) phosphorylation and contraction to the resting level. However, fractions of PGF(2alpha)-induced contraction and MLC(20) phosphorylation were resistant to @entity10 but were sensitive to @entity9 . @entity12 (10 microM), a @entity8 inhibitor, did not affect the phosphorylation of MLC(20) and the @entity3 caused by PGF(2alpha), thus excluding the possibility of the involvement of @entity8 in the PGF(2alpha)-induced MLC(20) phosphorylation. PGF(2alpha) increased phosphorylation at Thr654 of the @entity11 ( @entity11 ) of myosin phosphatase, which is a target of rho kinase, and @entity9 decreased the phosphorylation. These data suggest that the PGF(2alpha)-induced contraction is accompanied by the inhibition of MLC(20) dephosphorylation through rho kinase-induced @entity11 phosphorylation, leading to @entity1 sensitization of contraction. An actin-associated mechanism may also be involved in the PGF(2alpha)-induced sensitization.

title: Essential role of rho kinase in the @entity1 sensitization of XXXX -induced contraction of @entity0 aortae.

answer: @entity4


abstract: OBJECTIVE: This report describes our experience using a modified anterior levator resection approach in @entity1 @entity0 and presents the results from a consecutive series of @entity0 treated with this method. DESIGN: This was a retrospective case series study. @entity0 : Forty-one @entity0 with moderate and severe @entity1 were included. METHODS: All @entity0 underwent a modified anterior levator resection approach under local anesthesia. The procedure involved exposing Whitnall's ligament, dissecting and resecting the underlying levator muscle from Whitnall's ligament, and leaving the aponeurosis intact. All @entity0 underwent pre- and postoperative photography, and final outcomes were assessed after a minimum of 6 months. Outcome measures included pre- and post-marginal reflex distance ( @entity2 ), symmetry of height, contour, and complications. RESULTS: Forty-one @entity0 undergoing 56 procedures were included. The mean age of the @entity0 was 15 (13-18) years. The mean postoperative @entity2 was 3.45 mm. Thirty-four @entity0 achieved their desired lid height and contour, and 7 @entity0 had undercorrection, including 1 @entity0 with 2 mm of asymmetry, with a final success rate of 83% (34/41 @entity0 ). CONCLUSIONS: Our modified anterior levator resection approach had a high success rate and is particularly suitable for @entity0 with moderate and severe @entity1 .

title: Surgical correction of XXXX using a modified levator resection technique.

answer: @entity1


abstract: BACKGROUND: @entity6 is a rare cause (1-8 %) of @entity2 causing an important morbi-mortality in the newborn and the mother. AIM: To report 3 cases of early @entity2 due to S @entity1 . CASES REPORT: Three cases of early @entity2 due to @entity6 are reported. The three newborns were at term or near term babies with a vaginal delivery in two cases and a caesarean section in one case. They presented severe symptoms, with a progressive onset after birth, leading to hypoxemic @entity1 in one case and to @entity3 in two newborns associated with @entity4 in one case. @entity6 was isolated in the blood culture in two @entity0 with positive soluble antigens in the cerebrospinal fluid in one case and positive peripheral bacteriological swabs in the other case. In the third case, @entity6 was isolated in the tracheal sample of the newborn and his mother. @entity6 was sensitive to @entity5 in two @entity0 and of decreased sensitivity to @entity5 in one @entity0 . The clinical course was favourable in the three @entity0 after hospitalization in the intensive care unit. CONCLUSION: Early neonatal infections caused by S @entity1 are rare and are an important cause of morbi-mortality in the newborn and the mother.

title: [Early XXXX caused by Streptococcus pneumonias: report of 3 cases].

answer: @entity2


abstract: PURPOSE: To determine the prevalence of isolated hemodynamically significant stenoses of accessory renal arteries when the main renal arteries are patent. MATERIALS AND METHODS: In 68 adults (24 @entity0 , mean age, 67 years +/- 10; 44 @entity0 , mean age, 67 years +/- 12), angiograms that fulfilled the following criteria were studied: (a) technically adequate renal angiograms obtained to evaluate suspected @entity4 and (b) angiographically documented hemodynamically significant @entity2 of any renal artery. The percentage of kidneys and the percentage of @entity0 with hemodynamically significant isolated stenoses of accessory renal arteries were calculated. RESULTS: Eighty-seven kidneys in 68 @entity0 had hemodynamically significant @entity3 . Fifteen kidneys had 16 accessory renal arteries. Four accessory arteries in three @entity0 had hemodynamically significant stenoses. Only one of 68 @entity0 (1.5%) had an accessory artery @entity2 unaccompanied by a main @entity3 in either kidney; this @entity0 had bilateral hemodynamically significant accessory artery stenoses. Two @entity0 had coexistent hemodynamically significant stenoses of accessory and main renal arteries. CONCLUSION: The prevalence of a hemodynamically significant @entity2 isolated to an @entity1 was 1.5% in our study. Thus, failure to detect accessory renal arteries should not unduly affect the utility of a noninvasive test for detecting @entity4 .

title: Is it necessary to study accessory arteries when screening the renal arteries for XXXX ?

answer: @entity4


abstract: BACKGROUND: @entity3 is frequently observed at the intensive care unit, after surgery, and after toxic drug administration. A rise in serum @entity4 and a fall in urine output are consequences of much earlier injury to the most sensitive part of tubular cells located at the proximal tubule. The aim of the present study was to investigate the course of two cell-cycle arrest urinary biomarkers compared to serum @entity4 in four clinical settings: @entity6 , @entity2 , severe @entity3 , and chemotherapy-induced @entity0 . METHODS: A recently developed bedside test known as NephroCheck measures two urinary parameters: @entity7 ( @entity7 ) and @entity5 ( @entity5 ). The test is based on a sandwich immunoassay technique. The final test output, labeled AKIRisk, is shown as a numeric result. RESULTS: This report revealed that [ @entity7 ]        [ @entity5 ] in urine rise rapidly prior to any change in serum @entity4 . A unique feature of all four clinical settings is that a rapid decline predicts the recovery of kidney function. Besides, a subclinical @entity0 might be detected by the test. CONCLUSION: This bedside test detects biomarkers of @entity0 . A rapid decline in AKIRisk was associated with the restoration of kidney function, whereas a prolonged high AKIRisk score was associated with @entity1 . However, the dynamics seem to differ, depending on the cause and the extent of injury. Further studies will be needed to clarify the issue.

title: NephroCheck data compared to serum XXXX in various clinical settings.

answer: @entity4


abstract: BACKGROUND: The role of @entity2 in development of @entity1 ( @entity1 ) remains controversial. Earlier studies have reported inconsistent results, possibly because of their varying ability to adjust for confounding. The impact of longitudinal change in @entity2 on renal outcome has not been assessed previously. We aimed to study the impact of change in serum @entity2 (SUA) as well as baseline SUA on the development of @entity1 . METHODS: In a prospective cohort study, we assessed the associations between change in SUA during follow-up, baseline SUA and @entity1 (defined as albumin- @entity5 -ratio (ACR) >= 1.13  mg albumin/mmol @entity5 and/or @entity3   <   60  ml/ @entity4 .73  m(2)) in a large cohort from a general population participating in the Troms   Study (n   =   2637). @entity0 were stratified according to tertiles of change in SUA between baseline (1994/95) and follow-up 13  years later. (upper tertile: SUA increasing group, two lower tertiles: SUA non-increasing group). Logistic regression analysis was applied with @entity1 and each component of @entity1 after 7 and 13  years as the dependent variables. Adjustments were made for baseline @entity3 , cardiovascular risk factors, and the use of antihypertensive drugs including diuretics. RESULTS: After excluding @entity0 with @entity1 at baseline, SUA increasers, compared to SUA non-increasers, had a doubled risk of @entity1 after 7  years (odds ratio 2.00, (95  % CI 1.45, 2.75)). Odds ratio for @entity1 in SUA increasers after 13  years was 2.18 (95  % CI 1.71, 2.79). The risk of developing ACR >= 1.13  mg/mmol alone was not significantly increased after 7  years (odds ratio 1.30 (95  % CI 0.90, 1.89), but after 13  years (odds ratio 1.43 (95  % CI 1.09, 1.86)). An increase in baseline SUA of 59   mol/L (1  mg/dL) gave an odds ratio for @entity1 after 13  years of 1.16 (95  % CI 1.04, 1.29). CONCLUSION: An increase in SUA during follow-up was associated with an increased risk of developing @entity1 after 7 and 13  years.

title: XXXX is associated with microalbuminuria and decreased glomerular filtration rate in the general population during 7 and 13 years of follow-up: The Troms   Study.

answer: @entity2


abstract: OBJECTIVE: To study the influence of mutation of @entity4 of COL I A1 gene on the biochemical function of osteoblast, and the pathomechanism of @entity3 . METHODS: Spongy bones were obtained to culture osteoblast primarily during total hip or knee replacements. The genotype of osteoblast was identified with PCR-RFLP. The amount of mRNA of COL I A1 and collagen type I were determined by RT-PCR and ELISA. The growth of osteoblast, the activity of bone @entity2 , and the amount of @entity1 in cell matrix and @entity1 nodus were measured. RESULTS: Three genotypes GG, GT and TT in osteoblast were successfully identified. Compared with GG and GT genotypes, lower expression of mRNA of COL I A1 gene, lesser collagen type I, @entity1 in cell matrix, and @entity1 nodus were found in the cells with TT genotype (P < 0.01). No significant differences were found between GG and GT genotype (P > 0.05). There were no significant differences in age, growth of osteoblast, and activity of bone @entity2 among the three genotypes (P > 0.05). CONCLUSION: Cells with TT genotype have low expression of mRNA of COL I A1 gene and less collagen type I , @entity1 in cell matrix and @entity1 nodus. The lower amount of collagen type I synthesized by osteoblast can decrease the matrix outside the bone cells and result in insufficient site for @entity1 deposition. This may be the cause of lower @entity3 in @entity0 with TT genotype.

title: [Influence of mutation of XXXX of COL I A1 gene on the biochemical function of osteoblast].

answer: @entity4


abstract: BACKGROUND: Schefflera leucantha Viguier is used as a traditional medicine in Thailand and China to relieve chronic cough and @entity4 . However, little is known about its anti- @entity1 effects. OBJECTIVE: This study was designed to investigate the effects of S leucantha @entity8 extract (SLEE) on chemokine production by epidermal Langerhans cells (LCs) stimulated with peptidoglycan ( @entity7 ) from @entity6 and @entity2 release from mast cells. METHODS: LCs were purified from @entity0 epidermal cells using the panning method with anti-IA(d) monoclonal antibody. Chemokine production by LCs was investigated by reverse transcription polymerase chain reaction and enzyme-linked immunosorbent assay (ELISA). Mast cells for @entity2 release assay were induced by long-term culture of @entity0 spleen cells. @entity2 release from these mast cells was measured by a competitive ELISA. RESULTS: Production of the eosinophil chemoattractant @entity5 and the type 2 T helper (TH2)-associated chemokine @entity9 from @entity7 -stimulated LCs was significantly inhibited by SLEE. Furthermore, SLEE significantly decreased the release of @entity2 from mast cells by IgE-mediated degranulation. CONCLUSION: These results suggest that S leucantha may offer a new therapeutic approach for the control of @entity3 associated with @entity6 colonization through inhibition of the production of @entity1 mediators.

title: Inhibitory effects of Schefflera leucantha extract on production of XXXX mediators by Langerhans cells and mast cells.

answer: @entity1


abstract: @entity12 is the prototype of generalized @entity4 or what today are called @entity1 . In most cases it is impossible to detect a specific etiology. It is estimated that a causative diagnosis may be shown in approximately 10-37% of the cases, including, @entity17 , @entity13 , @entity7 such as @entity8 and 22q13.3 deletion syndrome, @entity16 , Smith-Magenis, Sotos, @entity18 , M  bius, Joubert and @entity15 , Ito's @entity14 , as well as certain cerebral malformations and several inherited @entity3 . The case of a 3-year old @entity0 is described, who was considered as autistic according to the criteria established by the DSM-IV manual for @entity2 . She showed a delay in psychomotor development since she was 18 months old; she pronounces very few words (10), points to some objects, does not look up and it is hard to establish eye contact with her. She has @entity9 and therefore, does not respond when called or when she is given orders, she is beginning to walk. She has not @entity5 . Laboratory tests showed an anion gap of 31.6 mEq/L, @entity6 : 2.55: mmol/L, @entity11 : 0.06 mmol/L, and elevated @entity6 to/ @entity11 ratio: 42.5. Under optical microscopy a muscular biopsy showed a reduction of the diameter of muscular fibers. The study of energy metabolism showed a partial @entity10 , which allowed us to conclude that this was a @entity10 with an autistic clinical spectrum.

title: XXXX associated to a @entity10 .

answer: @entity12


abstract: @entity12 is the prototype of generalized @entity4 or what today are called @entity1 . In most cases it is impossible to detect a specific etiology. It is estimated that a causative diagnosis may be shown in approximately 10-37% of the cases, including, @entity17 , @entity13 , @entity7 such as @entity8 and 22q13.3 deletion syndrome, @entity16 , Smith-Magenis, Sotos, @entity18 , M  bius, Joubert and @entity15 , Ito's @entity14 , as well as certain cerebral malformations and several inherited @entity3 . The case of a 3-year old @entity0 is described, who was considered as autistic according to the criteria established by the DSM-IV manual for @entity2 . She showed a delay in psychomotor development since she was 18 months old; she pronounces very few words (10), points to some objects, does not look up and it is hard to establish eye contact with her. She has @entity9 and therefore, does not respond when called or when she is given orders, she is beginning to walk. She has not @entity5 . Laboratory tests showed an anion gap of 31.6 mEq/L, @entity6 : 2.55: mmol/L, @entity11 : 0.06 mmol/L, and elevated @entity6 to/ @entity11 ratio: 42.5. Under optical microscopy a muscular biopsy showed a reduction of the diameter of muscular fibers. The study of energy metabolism showed a partial @entity10 , which allowed us to conclude that this was a @entity10 with an autistic clinical spectrum.

title: @entity12 associated to a XXXX .

answer: @entity10


abstract: OBJECTIVE: To determine the efficacy, tolerance and safety of subcutaneous injections of porcine type I collagen- @entity7 ( @entity8 ) in @entity0 with @entity2 ( @entity2 ). METHODS: Eleven @entity0 with active @entity2 on stable therapy with @entity3 ( @entity4 ) were enrolled in a 3 month prospective and longitudinal study. @entity0 were treated weekly with subcutaneous injections of 0.2 ml of collagen- @entity8 (1.7 mg of collagen) in the 8 most @entity1 . The primary endpoints included the Ritchie index (RI), swollen joint count, disease activity score (DAS), erythrocyte sedimentation rate (ESR), and @entity5 (CRP). The secondary endpoints included morning @entity6 , @entity1 intensity on a visual analog scale (VAS), and the Spanish-Health Assessment Questionnaire Disability Index (HAQ-DI). Improvement was determined using American College of Rheumatology (ACR) response criteria. RESULTS: Collagen- @entity8 was safe and well-tolerated and there were no adverse events. @entity0 had a statistically significant improvement (p < 0.05) in basal versus 3 month's treatment in morning @entity6 (Delta -32.3, -68.6%), RI (Delta -10.2, -46.4%), swollen joint count (Delta -10.7, -71.8%), VAS (Delta -39.9, -63.8%), HAQ-DI (Delta -0.5, -48.5%), DAS (Delta -1.35, -70.5%) and ACR20, 50, and 70 (80.0%; 60.0% and 20.0% respectively). We found no differences in serologic or hematologic variables. CONCLUSION: Collagen- @entity8 was a safe and well-tolerated drug for the short term treatment of @entity2 . The combination of collagen- @entity8 plus @entity4 was more efficacious than @entity4 alone. However, double-blind placebo-controlled phase II and III clinical trials are necessary to determine whether this drug could be useful in the longterm treatment of @entity2 .

title: Subcutaneous administration of polymerized-type I collagen for the treatment of @entity0 with XXXX . An open-label pilot trial.

answer: @entity2


abstract: OBJECTIVE: To determine the efficacy, tolerance and safety of subcutaneous injections of porcine type I collagen- @entity7 ( @entity8 ) in @entity0 with @entity2 ( @entity2 ). METHODS: Eleven @entity0 with active @entity2 on stable therapy with @entity3 ( @entity4 ) were enrolled in a 3 month prospective and longitudinal study. @entity0 were treated weekly with subcutaneous injections of 0.2 ml of collagen- @entity8 (1.7 mg of collagen) in the 8 most @entity1 . The primary endpoints included the Ritchie index (RI), swollen joint count, disease activity score (DAS), erythrocyte sedimentation rate (ESR), and @entity5 (CRP). The secondary endpoints included morning @entity6 , @entity1 intensity on a visual analog scale (VAS), and the Spanish-Health Assessment Questionnaire Disability Index (HAQ-DI). Improvement was determined using American College of Rheumatology (ACR) response criteria. RESULTS: Collagen- @entity8 was safe and well-tolerated and there were no adverse events. @entity0 had a statistically significant improvement (p < 0.05) in basal versus 3 month's treatment in morning @entity6 (Delta -32.3, -68.6%), RI (Delta -10.2, -46.4%), swollen joint count (Delta -10.7, -71.8%), VAS (Delta -39.9, -63.8%), HAQ-DI (Delta -0.5, -48.5%), DAS (Delta -1.35, -70.5%) and ACR20, 50, and 70 (80.0%; 60.0% and 20.0% respectively). We found no differences in serologic or hematologic variables. CONCLUSION: Collagen- @entity8 was a safe and well-tolerated drug for the short term treatment of @entity2 . The combination of collagen- @entity8 plus @entity4 was more efficacious than @entity4 alone. However, double-blind placebo-controlled phase II and III clinical trials are necessary to determine whether this drug could be useful in the longterm treatment of @entity2 .

title: Subcutaneous administration of polymerized-type I collagen for the treatment of XXXX with @entity2 . An open-label pilot trial.

answer: @entity0


abstract: OBJECTIVE: To evaluate the influence of polypectomy and anterior ethmoidectomy associated with intranasal applications of @entity4 on the recurrence of @entity1 . METHOD: Fifty one @entity0 (19 females, 32 males, mean age 43) undergoing polypectomy and anterior ethmoidectomy were included in the study. In 29 @entity0 , a @entity3 pellet soaked with @entity4 (3 x 10(-6) mol, dissolved in 70% @entity2 ) was left into the middle meatus for 20 min under local anaesthesia. As a control group, 22 @entity0 were treated with the @entity4 vehicle alone (70% @entity2 ). All @entity0 studied received the intranasal @entity4 or vehicle treatment once a week for 5 weeks. The clinical objective examination and the subjective evaluation of nasal obstruction, @entity5 were recorded by means of a visual analogic scale graded from 0 to 4 throughout the study. RESULT: @entity0 treated with intranasal @entity4 application reported 9 months later and 55 months later separately, a marked reduction of their subjective evaluation of nasal obstruction when compared to the pretreatment evaluation (P < 0.01). In contrast, @entity0 treated with the @entity4 vehicle alone did not have any significant improvement of their subjective evaluation of nasal obstruction. Subjective @entity5 was not modified by either treatment. Of 29 @entity0 with @entity4 treatment, 25 (86.2%) @entity0 (9 months later) and 20 (69%) @entity0 (55 months later) showed satisfactory result, compared to 10 (45.4%) @entity0 and 8 (36.4%) @entity0 separately in the control group, the difference was significant (P < 0.01). CONCLUSION: Intranasal @entity4 application can reduce polyp recurrence and nasal obstruction after polypectomy and ethmoidectomy.

title: [Effect of intranasal treatment with XXXX on polyp recurrence after polypectomy and ethmoidectomy].

answer: @entity4


abstract: OBJECTIVE: To study the pathological changes of @entity3 cases after the treatment of stereotactic radiosurgery. METHOD: 15 cases with recurrent or residual @entity4 of nasopharynx diagnosed as T1-4 N0M0 were selected, which had undergone previous radiotherapy. The @entity0 were treated by Gamma Knife while the isodose curve was 50% and the margin dose was 20 Gy. The nasopharynx biopsy was performed before the treatment and 1, 3, 6, 12 months after the treatment. The biopsy specimen was taken to make a pathological examination. RESULT: 1. Before the Gamma Knife treatment, @entity3 cell could be seen in the tissue; 2. 1-3 months after the treatment, cell @entity2 and acute @entity1 cell infiltration could be seen in the target; 3. 6-12 months after the treatment, infiltration of chronic @entity1 cell, proliferation of fibrous tissue and capillary could be found in the target. CONCLUSION: This research implies that the short-term pathological changes after the treatment of stereotactic radiosurgery can be defined as two phases: The first phase occurs from 1 to 3 months after the treatment called @entity2 period. The second phase occurs from 6 to 12 months after the Gamma Knife treatment named as absorption period.

title: [The pathological changes of XXXX cases treated by stereotactic radiosurgery].

answer: @entity3


abstract: The Extracranial-Intracranial (EC/IC) Bypass Procedure is a new method in order to try to increase the Intracranial Perfusion Pressure (ICPP). Postoperative patency of the bypass can be shown by means of Seldinger angiography. By this method no information however is obtained on the hemodynamic function of the bypass. @entity2 -Gee measures the Ophthalmic Artery Pressure (OAP) which is related to the ICPP. In this study @entity2 -Gee is performed without and subsequently with compression of the bypass. Quantification of the hemodynamic significance of the bypass is obtained by measuring the pressure decay in the ophthalmic arteries during this procedure. The Rest Pressure Difference (RPD), i.e. the pressure difference between the two ophthalmic arteries without bypass compression is measured. By subtracting the RPD from the BCD the remaining pressure is called the Net Bypass Pressure ( @entity3 ), i.e. the pressure difference, which the EC/IC bypass contributes to the ICPP. If, however, at constant systemic arterial blood pressure (SABP) the OAP drops during bypass compression on both sides, we hypothesize that the @entity3 is the sum of both drops, because, as a result of the interhemispheric steal mechanism, the less perfused hemisphere steals from the better perfused hemisphere. In a group of 40 @entity0 @entity2 -Gee without and subsequently with bypass compression was applied. Twenty two of 40 @entity2 -Gee's showed @entity3 's of 4 mm of @entity1 or more (55%). In the group of 29 @entity0 with unilateral internal carotid artery occlusion in 21 @entity0 (72%) an @entity3 of 4 mm of @entity1 or more was found (mean of 13 mm of @entity1 ).(ABSTRACT TRUNCATED AT 250 WORDS)

title: Ophthalmopneumoplethysmography ( XXXX -Gee) without and with bypass-compression for quantification of hemodynamic significance of superficial temporal artery-middle cerebral artery (STA-MCA) anastomosis.

answer: @entity2


abstract: OBJECTIVES: Sixteen national surveys of @entity3 in Japan from 1970 to 2000 have identified a total of 169,117 @entity0 with @entity3 . Based on that figure, 8,460 residents of Hokkaido probably have a history of @entity3 . It is also estimated that almost 270 Hokkaido residents would have @entity3 -related @entity2 . We underwent follow-up studies of Hokkaido residents > or = 15 years with @entity3 . METHODS: We mailed a questionnaire to the departments of internal medicine, cardiology or cardiovascular surgery inquiring about the health status of @entity0 with @entity3 at 451 hospitals with 20 or more beds in Hokkaido. RESULTS: We obtained replies from 185 hospitals (41.0%). Only 11 hospitals(5.9%) reported experience of @entity0 with @entity3 (with or without @entity2 ) at hospital follow-up. Detailed @entity0 histories for 60 @entity0 from 7 hospitals were obtained: Twenty @entity0 had @entity3 complicated with @entity2 , whereas 40 @entity0 had a history of @entity3 and no present @entity2 . Thirty-seven @entity0 without @entity2 were followed up at one hospital. The 60 @entity0 were aged from 15 to 36 years. Thirty-nine @entity0 (65%) were in the 15 to 20 year age bracket. @entity4 were recognized in 25 @entity0 (24 males and 1 female) with @entity3 (41.7%) at the onset of the disease. Twenty @entity0 had an @entity1 (s) in the left main trunk and/or the left anterior descending artery, and 13 @entity0 in the right coronary artery. There was a history of @entity5 in four @entity0 (6.7%) and nine @entity0 (15.0%) still suffered from @entity6 . Aortocoronary bypass surgery was performed in one @entity0 , whereas two @entity0 required percutaneous coronary intervention. CONCLUSIONS: Our study suggests that the majority of Hokkaido residents with @entity3 (with or without @entity2 ) are not being followed up at area hospitals. The characteristics of @entity0 who were followed up included age < or = 20 years, male sex and the presence of severe @entity2 other than circumflex involvement.

title: [Follow-up studies of Hokkaido residents with XXXX ].

answer: @entity3


abstract: BACKGROUND: We hypothesized that transfection of the gene for @entity0 @entity6 (hHGF) combined with cellular cardiomyoplasty might regenerate the impaired myocardium. METHODS AND RESULTS: We used a ligation model of proximal left anterior descending coronary artery of Lewis @entity1 . Two weeks after left anterior descending coronary artery ligation, three different treatments were conducted; 1) neonatal @entity1 cardiomyocytes group(10(6) cells, T group, n = 11), 2) HVJ-liposomes bearing the hHGF gene group (H group, n = 10), and 3) combined(T-H group, n = 10). The injection site was the scar area of @entity3 . For control, culture medium was injected (C group, n = 13). Echocardiography demonstrated that cardiac performance was significantly ameliorated in the T-H group 4 and 8 weeks after injection. Contrast echocardiography also showed a marked increase in myocardial perfusion in the T-H group but not in the other groups. In the T-H group, @entity5 and a marked @entity2 were observed histologically. In an immunohistochemical study, strong staining for beta 1-integrin, alpha- and beta-dystroglycan were found principally in the basement membrane of myocytes in the T-H group 8 weeks after transplantation, although there was weak immunoreactivity in the T group. CONCLUSIONS: hHGF gene transfection enhanced the cellular cardiomyoplasty possibly by stimulating angiogenesis, restoring the impaired extracellular matrix, and promoting the integration of the dissociated grafted myocytes. The combined effects might have lead to the improved cardiac performance. Thus, combined therapy may be a promising strategy for the treatment of @entity4 caused by @entity3 .

title: [Myocardial regeneration therapy for XXXX : @entity6 enhances the effect of cellular cardiomyoplasty].

answer: @entity4


abstract: BACKGROUND: We hypothesized that transfection of the gene for @entity0 @entity6 (hHGF) combined with cellular cardiomyoplasty might regenerate the impaired myocardium. METHODS AND RESULTS: We used a ligation model of proximal left anterior descending coronary artery of Lewis @entity1 . Two weeks after left anterior descending coronary artery ligation, three different treatments were conducted; 1) neonatal @entity1 cardiomyocytes group(10(6) cells, T group, n = 11), 2) HVJ-liposomes bearing the hHGF gene group (H group, n = 10), and 3) combined(T-H group, n = 10). The injection site was the scar area of @entity3 . For control, culture medium was injected (C group, n = 13). Echocardiography demonstrated that cardiac performance was significantly ameliorated in the T-H group 4 and 8 weeks after injection. Contrast echocardiography also showed a marked increase in myocardial perfusion in the T-H group but not in the other groups. In the T-H group, @entity5 and a marked @entity2 were observed histologically. In an immunohistochemical study, strong staining for beta 1-integrin, alpha- and beta-dystroglycan were found principally in the basement membrane of myocytes in the T-H group 8 weeks after transplantation, although there was weak immunoreactivity in the T group. CONCLUSIONS: hHGF gene transfection enhanced the cellular cardiomyoplasty possibly by stimulating angiogenesis, restoring the impaired extracellular matrix, and promoting the integration of the dissociated grafted myocytes. The combined effects might have lead to the improved cardiac performance. Thus, combined therapy may be a promising strategy for the treatment of @entity4 caused by @entity3 .

title: [Myocardial regeneration therapy for @entity4 : XXXX enhances the effect of cellular cardiomyoplasty].

answer: @entity6


abstract: AIM: To monitor the effect of adding @entity4 in paediatric @entity0 with @entity2 and @entity1 . METHODS: A case series of eight @entity0 with @entity2 whose focal @entity3 were not adequately controlled by their current anticonvulsants were monitored after @entity4 was added to their medications. If there was a 50% reduction in @entity3 frequency, then the other anticonvulsants were discontinued. Prolonged follow-up occurred for a minimum of 2 years. RESULTS: There were seven males and one female whose ages ranged from 4 years to 17 years. All had focal onset @entity3 , while seven also had secondarily generalised tonic @entity3 . @entity4 resulted in at least a 50% reduction in @entity3 frequency in seven, with no change in one. Three were able to wean successfully to monotherapy and remained @entity3 free for over 2 years. They had a prior history of infrequent @entity3 , one to six per year. Those who continued to require multiple anticonvulsants had a prior history of more frequent @entity3 , 6-50/year. @entity4 was well tolerated, and none ceased this because of side effects. CONCLUSION: @entity4 is likely to be an effective anticonvulsant in @entity0 and adolescents with @entity2 and infrequent but persistent focal @entity3 .

title: XXXX in @entity0 and adolescents with @entity1 and @entity2 .

answer: @entity4


abstract: AIM: To monitor the effect of adding @entity4 in paediatric @entity0 with @entity2 and @entity1 . METHODS: A case series of eight @entity0 with @entity2 whose focal @entity3 were not adequately controlled by their current anticonvulsants were monitored after @entity4 was added to their medications. If there was a 50% reduction in @entity3 frequency, then the other anticonvulsants were discontinued. Prolonged follow-up occurred for a minimum of 2 years. RESULTS: There were seven males and one female whose ages ranged from 4 years to 17 years. All had focal onset @entity3 , while seven also had secondarily generalised tonic @entity3 . @entity4 resulted in at least a 50% reduction in @entity3 frequency in seven, with no change in one. Three were able to wean successfully to monotherapy and remained @entity3 free for over 2 years. They had a prior history of infrequent @entity3 , one to six per year. Those who continued to require multiple anticonvulsants had a prior history of more frequent @entity3 , 6-50/year. @entity4 was well tolerated, and none ceased this because of side effects. CONCLUSION: @entity4 is likely to be an effective anticonvulsant in @entity0 and adolescents with @entity2 and infrequent but persistent focal @entity3 .

title: @entity4 in @entity0 and adolescents with XXXX and @entity2 .

answer: @entity1


abstract: AIM: To monitor the effect of adding @entity4 in paediatric @entity0 with @entity2 and @entity1 . METHODS: A case series of eight @entity0 with @entity2 whose focal @entity3 were not adequately controlled by their current anticonvulsants were monitored after @entity4 was added to their medications. If there was a 50% reduction in @entity3 frequency, then the other anticonvulsants were discontinued. Prolonged follow-up occurred for a minimum of 2 years. RESULTS: There were seven males and one female whose ages ranged from 4 years to 17 years. All had focal onset @entity3 , while seven also had secondarily generalised tonic @entity3 . @entity4 resulted in at least a 50% reduction in @entity3 frequency in seven, with no change in one. Three were able to wean successfully to monotherapy and remained @entity3 free for over 2 years. They had a prior history of infrequent @entity3 , one to six per year. Those who continued to require multiple anticonvulsants had a prior history of more frequent @entity3 , 6-50/year. @entity4 was well tolerated, and none ceased this because of side effects. CONCLUSION: @entity4 is likely to be an effective anticonvulsant in @entity0 and adolescents with @entity2 and infrequent but persistent focal @entity3 .

title: @entity4 in @entity0 and adolescents with @entity1 and XXXX .

answer: @entity2


abstract: AIM: To monitor the effect of adding @entity4 in paediatric @entity0 with @entity2 and @entity1 . METHODS: A case series of eight @entity0 with @entity2 whose focal @entity3 were not adequately controlled by their current anticonvulsants were monitored after @entity4 was added to their medications. If there was a 50% reduction in @entity3 frequency, then the other anticonvulsants were discontinued. Prolonged follow-up occurred for a minimum of 2 years. RESULTS: There were seven males and one female whose ages ranged from 4 years to 17 years. All had focal onset @entity3 , while seven also had secondarily generalised tonic @entity3 . @entity4 resulted in at least a 50% reduction in @entity3 frequency in seven, with no change in one. Three were able to wean successfully to monotherapy and remained @entity3 free for over 2 years. They had a prior history of infrequent @entity3 , one to six per year. Those who continued to require multiple anticonvulsants had a prior history of more frequent @entity3 , 6-50/year. @entity4 was well tolerated, and none ceased this because of side effects. CONCLUSION: @entity4 is likely to be an effective anticonvulsant in @entity0 and adolescents with @entity2 and infrequent but persistent focal @entity3 .

title: @entity4 in XXXX and adolescents with @entity1 and @entity2 .

answer: @entity0


abstract: PROBLEM: A successful pregnancy is contingent on maternal tolerance of the immunologically foreign fetus. @entity0 such as @entity4 arise in part due to an inappropriate immune response by the placenta. A number of molecules have been proposed to temper cellular response to pro-inflammatory mediators, including @entity5 and @entity6 . METHODS: Cytotrophoblast cells from healthy term placentas were treated with @entity2 in vitro and analyzed with qPCR and ELISA-based assays. Immunohistochemistry was performed on term villous sections and cultured trophoblasts. RESULTS: Treatment with @entity2 increased expression of @entity3 and @entity1 . Term villi express @entity5 in cytotrophoblasts and the syncytiotrophoblast, and @entity6 by the syncytiotrophoblast. Treatment of trophoblast cells with @entity2 increased @entity6 expression. CONCLUSION: These data describe a role for @entity2 in enhancing pro-inflammatory signals in in vitro syncytialized trophoblasts. Additionally, this represents the first time the @entity5 / @entity6 pathway has been implicated in a trophoblast response to a pro-inflammatory mediator.

title: The pro-inflammatory role of XXXX at the maternal-fetal interface.

answer: @entity2


abstract: INTRODUCTION: The approach of the residents of central @entity4 , @entity1 , to @entity2 in our conservative district is shaped by the effect of the culture. In emergency actions, many traditional approaches are preferred, using herbs and other available materials. Some of these approaches might be directly hazardous and some create danger indirectly as they prolong the treatment period. METHODS: The study was performed using a one-group pretest/posttest design. Data were collected between June 3, 2006, and August 28, 2007. Two thousand sixty mothers completed the sociodemographic pretest and survey and attended the educational program. The final sample included 1754 mothers who completed the sociodemographic and pretest survey, attended the educational program, and completed the posttest survey. The posttest survey was administered 6 months following the educational program. RESULTS: In this study; the percentage of mothers resorting to traditional approaches in the pretest were at burns, 29.0%; lacerations, 21.4%; @entity0 , 25.7%; and @entity3 , 45.1%; and in the posttest burns, 16.1%; lacerations, 12.7%; @entity0 , 15.6%; and @entity3 , 34.4%. Mothers with higher educational levels were less likely to use traditional practices and the educational program significantly reduced the prevalence of using traditional practices. The training program had a positive effect in decreasing the incidence of resorting to traditional practices for certain @entity2 . DISCUSSION: It was proven that the application of various harmful traditional practices had been used in first aid cases and that the rate decreased in the post training period. It is interesting to note that an additional 540 mothers who did not complete the pretest and sociodemographic questionnaire also attended the educational program because word of the program had spread throughout the region.

title: The effect of training programs on traditional approaches that mothers use in XXXX .

answer: @entity2